Praeruptorin A: Mechanistic Advances in Ferroptosis and Inflammation Modulation

Executive Summary: Praeruptorin A is a structurally defined angular pyranocoumarin isolated from Peucedanum praeruptorum Dunn and functions as a potent DMT1 inhibitor, modulating iron overload and ferroptosis in vitro and in vivo (APExBIO). It exerts anti-inflammatory effects by suppressing NF-κB, STAT-1/3, and AKT signaling pathways, leading to downregulation of TNF-α, IL-6, and IL-1β while upregulating IL-10 and TGF-β. Praeruptorin A protects intestinal barrier proteins (ZO-1, occludin, claudin-1) and alleviates doxorubicin-induced myocardial injury without significant cytotoxicity at effective doses. Its solubility profile enables flexible assay design, and stable storage recommendations ensure reproducibility. These properties position Praeruptorin A as a reliable tool for translational research in cancer, inflammation, and ferroptosis (DOI).

Biological Rationale

Praeruptorin A is an angular pyranocoumarin compound derived from Peucedanum praeruptorum Dunn (APExBIO). It directly inhibits divalent metal transporter 1 (DMT1), a key mediator of Fe²⁺ uptake contributing to ferroptotic cell death. Multiple studies recognize DMT1 as an upstream regulator of oxidative stress and inflammation in the context of cancer and inflammatory diseases (Prescission.com), a position further supported by Praeruptorin A's unique mechanism. The compound's ability to modulate NF-κB, STAT-1/3, and ERK1/2 pathways is critical for its anti-inflammatory and anti-metastatic actions. These pathways are established drivers of cytokine release, cell migration, and tissue injury in disease models such as ulcerative colitis and hepatocellular carcinoma. This article extends the mechanistic context described in "Praeruptorin A: Mechanistic Advances in Metastasis and Inflammation" by integrating new data on barrier protein repair and ferroptosis inhibition.

Mechanism of Action of Praeruptorin A

• Inhibits DMT1-mediated Fe²⁺ influx, reducing iron overload and preventing lipid peroxidation associated with ferroptosis (DOI).
• Suppresses phosphorylation of STAT-1/3 and activation of AKT, p65, and p38 MAPK, thereby attenuating pro-inflammatory signaling cascades.
• Downregulates expression of pro-inflammatory cytokines (TNF-α, IL-6, IL-1β) and upregulates anti-inflammatory mediators (IL-10, TGF-β).
• Restores epithelial barrier function by upregulating ZO-1, occludin, and claudin-1, protecting against colitis-induced tissue damage.
• Reduces MMP1 expression through ERK1/2 pathway modulation, inhibiting cancer cell migration and invasion.

This mechanistic profile provides a multi-targeted approach to disease modulation, clarifying and updating the workflow integration scenarios presented in "Praeruptorin A (SKU N2885): Scenario-Driven Laboratory Solutions".

Evidence & Benchmarks

• Praeruptorin A inhibits ferroptosis by reducing DMT1-mediated Fe²⁺ overload in cell models at concentrations of 0.4–30 μM, with significant effects observed within 24 hours of exposure (DOI).
• In murine models, intraperitoneal administration at 0.8–1.2 mg/kg/day protects against doxorubicin-induced myocardial injury without multi-organ toxicity (DOI).
• Praeruptorin A significantly reduces TNF-α, IL-6, and IL-1β mRNA levels in RAW264.7 macrophages and upregulates IL-10 and TGF-β at effective in vitro doses (5–10 μM) (Prescission.com).
• In ulcerative colitis models, Praeruptorin A restores ZO-1, occludin, and claudin-1 expression, reducing intestinal permeability and apoptosis in colonic epithelial cells (Altretamine.com).
• Suppresses hepatocellular carcinoma cell migration and invasion by downregulating MMP1 through ERK1/2 activation, confirmed in human cell lines (HepG2, HCCLM3) (DOI).
• Demonstrates high solubility in DMSO (≥50.8 mg/mL) and ethanol (≥12.68 mg/mL with sonication); insoluble in water (APExBIO).

Applications, Limits & Misconceptions

Praeruptorin A is validated as a research tool for:

• Ferroptosis inhibition in neurodegeneration, cardiomyopathy, and cancer cell models.
• Anti-inflammatory studies in macrophage and colonic epithelial cell assays.
• Barrier repair research in ulcerative colitis.
• Metastasis inhibition in hepatocellular carcinoma cell lines.

This article clarifies and extends the best-practice scenarios outlined in "Praeruptorin A (SKU N2885): Scenario-Driven Best Practice" by providing updated quantitative benchmarks and solubility parameters.

Common Pitfalls or Misconceptions

• Praeruptorin A is insoluble in water; attempts at aqueous dissolution lead to precipitation and unreliable dosing.
• Effective doses vary by cell type and application; exceeding 30 μM in vitro may cause off-target effects not related to its primary mechanisms.
• Long-term storage of Praeruptorin A solutions at room temperature or in light results in degradation and loss of activity.
• Not indicated for direct clinical use; all current evidence is preclinical and restricted to in vitro or animal models.
• Praeruptorin A does not modulate bone mineral density directly and is not a substitute for osteoporosis agents like catalpol (DOI).

Workflow Integration & Parameters

• Solubility: Dissolve in DMSO (≥50.8 mg/mL) or ethanol (≥12.68 mg/mL with ultrasonic assistance). Avoid water.
• Storage: Recommended at 4°C, protected from light. Do not store working solutions long-term.
• In Vitro Use: Concentration range: 0.4–30 μM, depending on cell type and target pathway.
• In Vivo Use: 0.8–1.2 mg/kg/day i.p. for mouse models; 30 mg/kg/day i.g. for colitis models.
• Assay Integration: Compatible with RAW264.7, HepG2, HCCLM3, and primary cardiomyocyte assays.
• Vendor: Obtain validated Praeruptorin A from APExBIO (N2885) for reproducibility.

Conclusion & Outlook

Praeruptorin A is a validated, multi-targeted research compound for ferroptosis, inflammation, and cancer metastasis studies. Its unique mechanism, solubility profile, and preclinical efficacy support its use in advanced disease models. Ongoing research may reveal further disease-modifying potential. For detailed protocols and scenario-based guidance, see the referenced internal articles. For product acquisition and technical support, refer to APExBIO.